$BGNE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BeiGene, Ltd..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in BeiGene, Ltd.. Get notifications about new insider transactions in BeiGene, Ltd. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 21 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Option Exercise | A | 26.53 | 241,839 | 6,415,989 | 241,839 | |
| Jun 21 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Option Exercise | A | 26.53 | 241,839 | 6,415,989 | 241,839 | |
| Jun 21 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Grant | A | 0.00 | 39,000 | 0 | 5,786,271 | 5.7 M to 5.8 M (+0.68 %) |
| Jun 21 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Grant | A | 0.00 | 39,000 | 0 | 5,786,271 | 5.7 M to 5.8 M (+0.68 %) |
| Jun 03 2021 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 69,000 | 0 | 2,754,129 | 2.8 M to 2.8 M (-2.44 %) |
| Jun 03 2021 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 69,000 | 0 | 2,754,129 | 2.8 M to 2.8 M (-2.44 %) |
| May 12 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Option Exercise | M | 0.01 | 88,231 | 882 | 4 | |
| May 12 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 303.10 | 389 | 117,906 | 0 | 389 to 0 (-100.00 %) |
| May 12 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 302.21 | 311 | 93,988 | 389 | 700 to 389 (-44.43 %) |
| May 12 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 300.20 | 1,594 | 478,518 | 700 | 2.3 K to 700 (-69.49 %) |
| May 12 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 299.40 | 1,100 | 329,340 | 2,294 | 3.4 K to 2.3 K (-32.41 %) |
| May 12 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Buy | M | 0.13 | 3,394 | 441 | 3,394 | 0 to 3.4 K |
| May 12 2021 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Buy | M | 0.13 | 44,109 | 5,734 | 5,747,271 | 5.7 M to 5.7 M (+0.77 %) |
| May 05 2021 | BGNE | BeiGene, Ltd. | Wu Xiaobin | President, COO & GM ... | Sell | S | 343.00 | 6,715 | 2,303,245 | 0 | 6.7 K to 0 (-100.00 %) |
| May 05 2021 | BGNE | BeiGene, Ltd. | Wu Xiaobin | President, COO & GM ... | Sell | S | 343.00 | 6,715 | 2,303,245 | 0 | 6.7 K to 0 (-100.00 %) |
| May 03 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 19,500 | 44,265 | 246,575 | |
| May 03 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 358.62 | 200 | 71,724 | 0 | 200 to 0 (-100.00 %) |
| May 03 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 356.25 | 300 | 106,876 | 200 | 500 to 200 (-60.00 %) |
| May 03 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 355.12 | 400 | 142,046 | 500 | 900 to 500 (-44.44 %) |
| May 03 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 353.94 | 300 | 106,182 | 900 | 1.2 K to 900 (-25.00 %) |
| May 03 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 352.67 | 200 | 70,534 | 1,200 | 1.4 K to 1.2 K (-14.29 %) |
| May 03 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 350.25 | 100 | 35,025 | 1,400 | 1.5 K to 1.4 K (-6.67 %) |
| May 03 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Buy | M | 29.49 | 1,500 | 44,235 | 1,500 | 0 to 1.5 K |
| Mar 31 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 19,500 | 44,265 | 266,075 | |
| Mar 31 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 326.29 | 227 | 74,067 | 0 | 227 to 0 (-100.00 %) |
| Mar 31 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 325.56 | 200 | 65,112 | 227 | 427 to 227 (-46.84 %) |
| Mar 31 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 324.14 | 378 | 122,525 | 427 | 805 to 427 (-46.96 %) |
| Mar 31 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 323.31 | 395 | 127,706 | 805 | 1.2 K to 805 (-32.92 %) |
| Mar 31 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 321.94 | 300 | 96,582 | 1,200 | 1.5 K to 1.2 K (-20.00 %) |
| Mar 31 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Buy | M | 29.49 | 1,500 | 44,235 | 1,500 | 0 to 1.5 K |
| Mar 16 2021 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 80,000 | 0 | 2,827,829 | 2.9 M to 2.8 M (-2.75 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 19,500 | 44,265 | 285,575 | |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 19,500 | 44,265 | 285,575 | |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 322.33 | 600 | 193,398 | 0 | 600 to 0 (-100.00 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 322.33 | 600 | 193,398 | 0 | 600 to 0 (-100.00 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 321.21 | 400 | 128,485 | 600 | 1,000 to 600 (-40.00 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 321.21 | 400 | 128,485 | 600 | 1,000 to 600 (-40.00 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 319.67 | 300 | 95,902 | 1,000 | 1.3 K to 1,000 (-23.08 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 319.67 | 300 | 95,902 | 1,000 | 1.3 K to 1,000 (-23.08 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 317.52 | 100 | 31,752 | 1,300 | 1.4 K to 1.3 K (-7.14 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 317.52 | 100 | 31,752 | 1,300 | 1.4 K to 1.3 K (-7.14 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 315.62 | 100 | 31,562 | 1,400 | 1.5 K to 1.4 K (-6.67 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 315.62 | 100 | 31,562 | 1,400 | 1.5 K to 1.4 K (-6.67 %) |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Buy | M | 29.49 | 1,500 | 44,235 | 1,500 | 0 to 1.5 K |
| Mar 02 2021 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Buy | M | 29.49 | 1,500 | 44,235 | 1,500 | 0 to 1.5 K |
| Jan 19 2021 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Option Exercise | M | 0.50 | 163,800 | 81,900 | 649,000 | |
| Jan 19 2021 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Option Exercise | M | 0.50 | 18,200 | 9,100 | 812,800 | |
| Jan 19 2021 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 345.54 | 5,606 | 1,937,087 | 0 | 5.6 K to 0 (-100.00 %) |
| Jan 19 2021 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 344.38 | 6,994 | 2,408,602 | 5,606 | 12.6 K to 5.6 K (-55.51 %) |
| Jan 19 2021 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Buy | M | 6.50 | 12,600 | 81,900 | 12,600 | 0 to 12.6 K |
| Jan 19 2021 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 345.15 | 300 | 103,546 | 0 | 300 to 0 (-100.00 %) |
| Jan 19 2021 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 344.28 | 1,100 | 378,710 | 300 | 1.4 K to 300 (-78.57 %) |
| Jan 19 2021 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Buy | M | 6.50 | 1,400 | 9,100 | 1,400 | 0 to 1.4 K |
| Dec 30 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 19,500 | 44,265 | 324,575 | |
| Dec 30 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 252.86 | 300 | 75,859 | 0 | 300 to 0 (-100.00 %) |
| Dec 30 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 251.58 | 300 | 75,475 | 300 | 600 to 300 (-50.00 %) |
| Dec 30 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 249.88 | 200 | 49,975 | 600 | 800 to 600 (-25.00 %) |
| Dec 30 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 247.98 | 200 | 49,595 | 800 | 1,000 to 800 (-20.00 %) |
| Dec 30 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 246.02 | 300 | 73,807 | 1,000 | 1.3 K to 1,000 (-23.08 %) |
| Dec 30 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 244.90 | 200 | 48,979 | 1,300 | 1.5 K to 1.3 K (-13.33 %) |
| Dec 30 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Buy | M | 29.49 | 1,500 | 44,235 | 1,500 | 0 to 1.5 K |
| Dec 18 2020 | BGNE | BeiGene, Ltd. | AMGEN INC | 10% Owner | Grant | A | 260.95 | 25,762 | 6,722,504 | 18,778,273 | 18.8 M to 18.8 M (+0.14 %) |
| Dec 18 2020 | BGNE | BeiGene, Ltd. | AMGEN INC | 10% Owner | Grant | A | 260.95 | 25,762 | 6,722,504 | 18,778,273 | 18.8 M to 18.8 M (+0.14 %) |
| Dec 17 2020 | BGNE | BeiGene, Ltd. | AMGEN INC | 10% Owner | Grant | A | 260.54 | 74,624 | 19,442,507 | 18,752,511 | 18.7 M to 18.8 M (+0.40 %) |
| Dec 17 2020 | BGNE | BeiGene, Ltd. | AMGEN INC | 10% Owner | Grant | A | 248.26 | 85,573 | 21,244,456 | 18,677,887 | 18.6 M to 18.7 M (+0.46 %) |
| Dec 17 2020 | BGNE | BeiGene, Ltd. | AMGEN INC | 10% Owner | Grant | A | 239.31 | 67,941 | 16,258,723 | 18,592,314 | 18.5 M to 18.6 M (+0.37 %) |
| Dec 17 2020 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Gift | G | 0.00 | 165,295 | 0 | 5,703,162 | 5.9 M to 5.7 M (-2.82 %) |
| Dec 17 2020 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Gift | G | 0.00 | 165,295 | 0 | 5,703,162 | 5.9 M to 5.7 M (-2.82 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Option Exercise | M | 0.50 | 2,600,000 | 1,300,000 | 831,000 | |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 232.19 | 700 | 162,532 | 0 | 700 to 0 (-100.00 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 231.11 | 17,456 | 4,034,303 | 700 | 18.2 K to 700 (-96.14 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 230.51 | 24,842 | 5,726,245 | 18,156 | 43 K to 18.2 K (-57.77 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 229.18 | 9,752 | 2,234,962 | 42,998 | 52.8 K to 43 K (-18.49 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 228.23 | 5,885 | 1,343,126 | 52,750 | 58.6 K to 52.8 K (-10.04 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 228.10 | 400 | 91,240 | 58,635 | 59 K to 58.6 K (-0.68 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 227.72 | 7,500 | 1,707,920 | 59,035 | 66.5 K to 59 K (-11.27 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 227.08 | 15,062 | 3,420,268 | 66,535 | 81.6 K to 66.5 K (-18.46 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 226.40 | 6,203 | 1,404,377 | 81,597 | 87.8 K to 81.6 K (-7.06 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 225.24 | 4,100 | 923,480 | 87,800 | 91.9 K to 87.8 K (-4.46 %) |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Buy | M | 6.50 | 91,900 | 597,350 | 91,900 | 0 to 91.9 K |
| Dec 16 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Buy | M | 0.50 | 1,405,300 | 702,650 | 1,573,715 | 168.4 K to 1.6 M (+834.43 %) |
| Dec 15 2020 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Gift | G | 0.00 | 545,597 | 0 | 545,597 | 0 to 545.6 K |
| Dec 15 2020 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Gift | G | 0.00 | 545,597 | 0 | 6,790,656 | 7.3 M to 6.8 M (-7.44 %) |
| Dec 15 2020 | BGNE | BeiGene, Ltd. | OYLER JOHN | Chief Executive Off ... | Gift | G | 0.00 | 1,591,317 | 0 | 7,336,253 | 8.9 M to 7.3 M (-17.82 %) |
| Dec 14 2020 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Gift | G | 0.00 | 1,244,542 | 0 | 1,244,542 | 0 to 1.2 M |
| Dec 14 2020 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Gift | G | 0.00 | 1,244,542 | 0 | 5,868,457 | 7.1 M to 5.9 M (-17.50 %) |
| Dec 14 2020 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Gift | G | 0.00 | 88,010 | 0 | 7,112,999 | 7.2 M to 7.1 M (-1.22 %) |
| Dec 08 2020 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 589,849 | 0 | 2,907,829 | 3.5 M to 2.9 M (-16.86 %) |
| Dec 08 2020 | BGNE | BeiGene, Ltd. | Glazer Donald W. | Director | Gift | G | 0.00 | 589,849 | 0 | 2,907,829 | 3.5 M to 2.9 M (-16.86 %) |
| Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | S | 220.50 | 1,386,033 | 305,620,277 | 10,811,048 | 12.2 M to 10.8 M (-11.36 %) |
| Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | S | 220.50 | 125,513 | 27,675,617 | 979,003 | 1.1 M to 979 K (-11.36 %) |
| Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Gift | G | 0.00 | 13,516 | 0 | 10,418 | 23.9 K to 10.4 K (-56.47 %) |
| Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Gift | G | 0.00 | 13,516 | 0 | 10,418 | 23.9 K to 10.4 K (-56.47 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 19,500 | 44,265 | 344,075 | |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 285.05 | 96 | 27,365 | 0 | 96 to 0 (-100.00 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 278.92 | 100 | 27,892 | 96 | 196 to 96 (-51.02 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 277.22 | 100 | 27,722 | 196 | 296 to 196 (-33.78 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 275.45 | 100 | 27,545 | 296 | 396 to 296 (-25.25 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 269.05 | 100 | 26,905 | 396 | 496 to 396 (-20.16 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 266.75 | 300 | 80,025 | 496 | 796 to 496 (-37.69 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 264.50 | 200 | 52,900 | 796 | 996 to 796 (-20.08 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 263.28 | 100 | 26,328 | 996 | 1.1 K to 996 (-9.12 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 262.06 | 200 | 52,411 | 1,096 | 1.3 K to 1.1 K (-15.43 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 260.06 | 100 | 26,006 | 1,296 | 1.4 K to 1.3 K (-7.16 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 256.00 | 104 | 26,624 | 1,396 | 1.5 K to 1.4 K (-6.93 %) |
| Dec 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Buy | M | 29.49 | 1,500 | 44,235 | 1,500 | 0 to 1.5 K |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 19,500 | 44,265 | 363,575 | |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 19,500 | 44,265 | 363,575 | |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 301.51 | 100 | 30,151 | 0 | 100 to 0 (-100.00 %) |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 301.51 | 100 | 30,151 | 0 | 100 to 0 (-100.00 %) |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 300.70 | 139 | 41,798 | 100 | 239 to 100 (-58.16 %) |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 300.70 | 139 | 41,798 | 100 | 239 to 100 (-58.16 %) |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 299.88 | 1,261 | 378,144 | 239 | 1.5 K to 239 (-84.07 %) |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 299.88 | 1,261 | 378,144 | 239 | 1.5 K to 239 (-84.07 %) |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Buy | M | 29.49 | 1,500 | 44,235 | 1,500 | 0 to 1.5 K |
| Nov 02 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Buy | M | 29.49 | 1,500 | 44,235 | 1,500 | 0 to 1.5 K |
| Oct 20 2020 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 320.00 | 5,000 | 1,600,000 | 0 | 5 K to 0 (-100.00 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Wang Xiaodong | Director | Sell | S | 300.00 | 5,000 | 1,500,000 | 0 | 5 K to 0 (-100.00 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Wu Xiaobin | President & GM Chin ... | Sell | S | 300.00 | 4,000 | 1,200,000 | 0 | 4 K to 0 (-100.00 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Wu Xiaobin | President & GM Chin ... | Sell | S | 300.00 | 4,000 | 1,200,000 | 0 | 4 K to 0 (-100.00 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Option Exercise | M | 0.50 | 182,000 | 91,000 | 3,431,000 | |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Option Exercise | M | 0.50 | 182,000 | 91,000 | 3,431,000 | |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 304.15 | 300 | 91,245 | 0 | 300 to 0 (-100.00 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 304.15 | 300 | 91,245 | 0 | 300 to 0 (-100.00 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 303.24 | 1,869 | 566,757 | 300 | 2.2 K to 300 (-86.17 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 303.24 | 1,869 | 566,757 | 300 | 2.2 K to 300 (-86.17 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 302.11 | 2,831 | 855,260 | 2,169 | 5 K to 2.2 K (-56.62 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 302.11 | 2,831 | 855,260 | 2,169 | 5 K to 2.2 K (-56.62 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 300.88 | 1,499 | 451,024 | 5,000 | 6.5 K to 5 K (-23.07 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 300.88 | 1,499 | 451,024 | 5,000 | 6.5 K to 5 K (-23.07 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 300.09 | 2,001 | 600,469 | 6,499 | 8.5 K to 6.5 K (-23.54 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 300.09 | 2,001 | 600,469 | 6,499 | 8.5 K to 6.5 K (-23.54 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 298.97 | 1,000 | 298,966 | 8,500 | 9.5 K to 8.5 K (-10.53 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 298.97 | 1,000 | 298,966 | 8,500 | 9.5 K to 8.5 K (-10.53 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 297.98 | 1,200 | 357,573 | 9,500 | 10.7 K to 9.5 K (-11.21 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 297.98 | 1,200 | 357,573 | 9,500 | 10.7 K to 9.5 K (-11.21 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 296.47 | 500 | 148,237 | 10,700 | 11.2 K to 10.7 K (-4.46 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 296.47 | 500 | 148,237 | 10,700 | 11.2 K to 10.7 K (-4.46 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 295.73 | 568 | 167,973 | 11,200 | 11.8 K to 11.2 K (-4.83 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 295.73 | 568 | 167,973 | 11,200 | 11.8 K to 11.2 K (-4.83 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 294.92 | 1,415 | 417,313 | 11,768 | 13.2 K to 11.8 K (-10.73 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 294.92 | 1,415 | 417,313 | 11,768 | 13.2 K to 11.8 K (-10.73 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 293.26 | 817 | 239,596 | 13,183 | 14 K to 13.2 K (-5.84 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Sell | S | 293.26 | 817 | 239,596 | 13,183 | 14 K to 13.2 K (-5.84 %) |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Buy | M | 6.50 | 14,000 | 91,000 | 14,000 | 0 to 14 K |
| Oct 07 2020 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Buy | M | 6.50 | 14,000 | 91,000 | 14,000 | 0 to 14 K |
| Oct 01 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Option Exercise | M | 2.27 | 19,500 | 44,265 | 383,075 | |
| Oct 01 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 283.83 | 102 | 28,950 | 0 | 102 to 0 (-100.00 %) |
| Oct 01 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 281.75 | 468 | 131,859 | 102 | 570 to 102 (-82.11 %) |
| Oct 01 2020 | BGNE | BeiGene, Ltd. | Huang Jane | CMO, Hematology | Sell | S | 280.65 | 730 | 204,875 | 570 | 1.3 K to 570 (-56.15 %) |